Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Go back to Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration| (NASDAQ: KOD) | Delayed: 87.72 -5.25 (5.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.97 | 52 Week High | $ | |||
| Open | $91.14 | 52 Week Low | $ | |||
| Day High | $94.64 | P/E | N/A | |||
| Day Low | $87.29 | EPS | $ | |||
| Volume | 943,039 | |||||



